Because of PPHM AZN news. Back to the PFE attempt to buy AZN for $118 BILLION!!!
Pfizer is moving on from last year's pursuit of AstraZeneca ($AZN), a $118 billion gambit driven largely by the allure of that company's immuno-oncology pipeline. In the ensuing months, Pfizer struck a slew of deals to cobble together some promising new assets that could help it catch up with the titans of the field, paying Merck KGaA$850 million up front for the PD-L1 inhibitor MSB0010718C and promising as much as $2 billion more to collaborate on up to 20 new cancer immunotherapies.
The deal took the pressure off of Pfizer and its business development squad in the aftermath of the AstraZeneca debacle, CEO Ian Read said last month, adding that "our research pipeline, middle stage to late stage, is strong, and I would rather take our capital right now and direct it to opportunities to accelerate EPS growth."
The numbers for IO are staggering and if Bavituximab does indeed increse ORR by 200-300% for PD-1 types then PPHM will be the benefactor of many of these BILLIONS that are being diverted to "collaborations"
Maybe one of Sunstars "collabnerships"
On the topic of collaborations...is it me or has that word become status quo just recently? Kind of like when you buy a new car and you then see that same car EVERYWHERE?
ritual...maybe a call to wish your friend the best and your joy that your friend is still with us.... : )
wook
News 
Market Data 
Discover 
